bpc-157 clinicaltrials.gov nct – Research Peptide US HCPs: #CAVT, now proven
Description
Why ARA-290 Is Different from Erythropoietin Erythropoietin: Increases red blood cell production Raises hematocrit Increases thrombosis risk at high levels ARA-290: Does not affect red blood cells Does not raise hematocrit Does not increase clotting risk This distinction makes ARA-290 suitable for chronic use in inflammatory and neurologic conditions , where EPO would be unsafe
This designation is relevant to its use as a nutraceutical, not as an injected research compound
+ Niacinamide-B3 Helps release energy from nutrients
This condition can have a devastating effect whatever the cause
